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Introduction
The proteasome is a multimeric protease complex that is central to the highly-regulated ubiquitinproteasome protein degradation system (Shen et al., 2013) . The proteasome plays a key role in regulating numerous signaling pathways involved in cell proliferation, cell cycle control, and apoptosis, which are often found to be dysregulated in malignant cells (Adams, 2004; Mani and Gelmann, 2005) . During the past decade, proteasome inhibition has proven to be an effective anti-cancer strategy with the FDA approval and revolutionary success of the first-in-class proteasome inhibitor agent bortezomib (Velcade ® , BTZ) in the treatment of multiple myeloma (Kumar et al., 2008) . To improve upon the success of BTZ, a second-generation, more selective proteasome inhibitor carfilzomib (Kyprolis ® , CFZ) was approved recently (Arastu-Kapur et al., 2011; Chen et al., 2011) . CFZ is a tetrapeptide equipped with an epoxyketone warhead that binds to the active site of the proteasome irreversibly (Kim and Crews, 2013) .
CFZ has demonstrated efficacy in both BTZ-naïve and BTZ-resistant patients, and possesses a more favorable toxicity profile compared to BTZ (Jagannath et al., 2012; Jakubowiak et al., 2012; Vij et al., 2012) . With these improvements, CFZ along with lenalidomide and dexamethasone has been recently shown to provide unprecedented benefit in patients with multiple myeloma (Stewart et al., 2015) .
Due to its promising anti-cancer activities and favorable toxicity profile, CFZ has also been explored as a potential therapeutic for malignancies other than multiple myeloma. However, despite the excellent efficacy observed in preclinical models of solid cancer (Yang et al., 2006; Demo et al., 2007; Ao et al., 2012) , CFZ demonstrated disappointing results clinically when tested in patients with advanced solid tumors (Papadopoulos et al., 2013) . Although the exact mechanisms underlying the discrepancies between the preclinical and clinical observations are currently unknown, one potential explanation is the rapid metabolic degradation of CFZ in vivo (Yang et al., 2011) . CFZ degradation in humans is mainly due to peptide cleavage and epoxide ring opening, resulting in plasma half-life of less than 30 min . We postulated that the fast metabolic inactivation of CFZ in the body might hinder the ability This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on May 29, 2017 jpet.aspetjournals.org Downloaded from JPET #226993 5 of the active drug to accumulate in solid cancer tissues, leading to insufficient target inhibition and poor clinical efficacy. Thus, increasing the metabolic stability of CFZ may serve as a strategy to improve its overall anti-cancer efficacy.
To overcome its poor water solubility issues, CFZ is currently formulated with sulfobutylether β -cyclodextrin for clinical delivery. However, SBECD offers little protective effects against metabolic degradation of CFZ in vivo , thus it would be useful to develop alternative CFZ formulations that can improve its metabolic stability in addition to solubility. Our current study explored the utility of polymer micelles in improving the metabolic stability of CFZ against enzyme-mediated degradation and delivering CFZ in a controlled manner. Polymer micelles are highly efficient in entrapping hydrophobic drug molecules inside the core to prevent the drugs from precipitating, binding to serum proteins, or being degraded by enzymes in the body (Sanvicens and Marco, 2008) . Additionally, polymer micelles are readily modified chemically or with attachment of surface ligands to control drug release patterns as well as cell-targeted drug delivery, making them versatile vehicles for delivery (Zhang et al., 2008; Ahmad et al., 2014) . Previous studies have also shown that polymer micelles can significantly reduced toxicity and improve anticancer activity of chemotherapeutics by achieving sustained drug release and increasing drug exposure to cancer cells (Tan et al., 2013; Werner et al., 2013 ).
In our current study, we prepared micelle particles composed of biodegradable block copolymers poly-(ethylene glycol) (PEG) and poly-(caprolactone) (PCL), both of which are generally recognized as safe by the FDA. The hydrophilic PEG can improve the solubility as well as increase the circulation time of the particles inside the body (Knop et al., 2010) while the hydrophobic PCL portions readily interact with CFZ to allow efficient drug encapsulation (Adams et al., 2003) . We prepared six different formulations with varying molecular weights of the PEG-PCL block to improve drug loading and with calcium phosphate (CP) or deoxycholic acid (DCA) excipients to modulate drug release. To simplify the polymer micelle formulation, we used PEG end-capped with a methoxy group in our study.
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Preparation of CFZ-loaded polymer micelles
We prepared a total of six CFZ-loaded polymer micelle formulations in this study as summarized in Table   1 : CFZ-loaded micelles, prepared from PEG-PCL 5-2 or PEG-PCL 5-5, with CP, DCA, or no excipient.
In a 50 mL round-bottom flask, 1 mL CFZ (1 mg/mL ethanol) and 100 μ L PEG-PCL (100 mg/mL ethanol) stock solutions were mixed at 60°C in the presence of additives: 20 μ L ethanol was added for excipient-free micelles, 20 μ L Na 2 HPO 4 (10 mg/mL in water) for CP-containing micelles, and 20 μ L DCA (10 mg/mL in ethanol) for DCA-containing micelles. Ethanol was evaporated under reduced pressure by using a rotatory evaporator to create a thin film at the bottom of each flask. The thin film was rehydrated with deionized water and gently mixed to allow PEG-PCL to self-assemble into polymer micelles entrapping CFZ. 8 was transferred to a conical tube and centrifuged to remove insoluble free drug, insoluble excipients, and other impurities. The supernatant containing CFZ-loaded micelles was collected and divided into tubes for freeze-drying. Freeze-dried micelles were weighed and stored at -20°C until use. To ensure no substantial degradation of CFZ occurs under these conditions, control experiments using free CFZ were carried out and CFZ integrity was assessed using HPLC. The extent of drug loading was determined by mass percent composition of CFZ in total CFZ-loaded micelles (w/w %). We quantified CFZ in micelles by high performance liquid chromatography (HPLC, Shimadzu LC20 system, Agilent XDB-C18 column equipped with a photo diode array detector (SPD-M20A using a mobile phase of H 2 O:CH 3 CN with 0.1% formic acid (45:55, v/v) at a flow rate of 1 mL/min, 40°C)). Encapsulation efficiency was defined as the percent of drug encapsulated to the drug added. Drug loading efficiency was defined as the weight percent of drug encapsulated to the weight of polymer added. According to the CFZ w/w %, we reconstituted freeze-dried micelles in water or buffer solutions and serial dilutions were made to prepare CFZ concentrations for experiments described below.
In vitro metabolism of CFZ polymer micelles in mouse liver homogenates
All animal studies were approved by the Institutional Animal Care and Use Committee at the University 
In vitro CFZ release profiles of polymer micelle formulations
Each formulation was dissolved in phosphate-buffered saline (PBS) to an equivalent CFZ concentration of 100 µM. For each sample, 100 µL of polymer micelle formulation was added to five dialysis cups and dialyzed against 1 L of PBS at 37 °C. A sample of 35 µL of each formulation was removed from the dialysis cups at 0, 1, 3, 6, 24, 48 and 72 h. CFZ concentration was analyzed by HPLC equipped with a photo diode array detector described above. Percent changes in CFZ concentrations were obtained by normalization to the value obtained at 0 h for each formulation. Drug release profiles for each formulation were analyzed by assuming second-order release kinetics, and by calculating the area under the curve (AUC) values.
Cell viability assay
H460 and RPMI-8226 cells were seeded in 96-well plates at 5,000 and 10,000 cells per well, respectively.
Following overnight incubation, H460 and RPMI-8226 cells were treated with free drug or the polymer micelle formulations at 50 and 5 nM equivalent CFZ concentrations, respectively. Cell viability was measured using the CellTiter-Glo luminescent cell viability assay (Promega) following manufacturer's This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Preparation of polymer micelle particles
Our initial goal was to identify a polymer micelle formulation that will allow us to achieve improved metabolic stability of CFZ. We prepared six polymer micelle formulations of CFZ composed of PEG-PCL block copolymers with identical 5000 g/mole PEG portions and varying PCL portions to maximize drug loading (Table 1) (Table 1) .
Polymer micelle formulations improve CFZ metabolic stability to varying extents in vitro
The metabolic stability profiles of the six CFZ-containing micelle formulations were compared against free CFZ solution by measuring the rate of CFZ disappearance in the presence of mouse liver homogenates (Fig 1) . Our results showed that free CFZ rapidly disappears in the presence of mouse liver homogenates, with less than 10% of the active drug remaining in 10 min of incubation. In contrast, all six micelle formulations of CFZ had improved stability profiles, demonstrated by five of the six formulations with at least 50% of the active CFZ remaining after 20 min of incubation (Fig 1) . Among the six different Polymer micelle formulations exhibited varying rates of CFZ release over 72 hours Next, we characterized the CFZ release profiles of the micelle particles in vitro by measuring the rate of drug release from the particles over 72 h. All six formulations demonstrated rapid CFZ release in the first 20 h followed by a slower, sustained release for up to 72 h (Fig 2) . We fit the data to a two-phase decay model and obtained kinetic parameters for the fast-and slow-release phases ( Table 2 ). The t 1/2 values during the fast-release phase were similar among all six particles, averaging around 1 h. In comparison, the slow-phase release profiles differed substantially among the six formulations, with PM1, PM2-CP, and PM2-DCA being the slowest-releasing formulations (Table 2) . We also analyzed CFZ release from the polymer micelles by comparing area under the curve (AUC) over 72 hours. AUC analysis is a modelindependent analysis method that allows for direct comparison of release profiles. In the current study, the larger AUC values the formulations have, the more CFZ would remain with polymer micelles over time.
Our AUC analysis results showed that PM1, PM1-DCA, and PM2-DCA had the highest AUC values, corresponding to slower drug release, whereas PM1-CP, PM2 and PM2-CP had low AUC values, corresponding to faster drug release rates (Table 2) .
Polymer micelle formulations display comparable or improved anti-cancer activities compared to free CFZ
When tested in H460 human lung cancer cells, we found that four of the polymer micelle formulations had more potent cell-killing effects compared to free CFZ solution (Fig 3A) . To exclude the possibility that components of the micelle particles themselves contributed to the overall cytotoxicity, we also measured the cell-killing effects of empty micelle particles of both molecular weight compositions in 15 tumor infiltrating abilities, likely due to their smaller sizes compared to liposomes (Tsukioka et al., 2002; Bae et al., 2005) . However, as with any nanoparticle delivery systems, polymer micelles have drawbacks associated with their use in drug delivery. One of the major concerns with utilizing micelle-based delivery systems is their lack of stability in vivo due to disintegration of the particles in the body. In this regard, previous studies have demonstrated that PEG-PCL-based polymer micelle particles carrying the anticancer agent paclitaxel exerted more potent anti-cancer activity in a mouse xenograft model than taxol alone (Tan et al., 2013) . These results suggest that PEG-PCL-based micelles are structurally stable enough in vivo to reach the tumor sites.
We have made efforts to address concerns with micelle stability in our current study by including two PEG-PCL micelle particles with the added excipients CP and DCA. Our goals by incorporating such additives into our particles were to further stabilize micelle core structures and to control drug release. CP is a main biological component of bone and teeth, which has been investigated as a surface modification due to its biocompatibility and rigidity to improve the stability of the hydrophobic drug-loaded nanoparticle cores (Li et al., 2015) . In solution, calcium ions and phosphate ions react to form solid calcium phosphate. Micelles or other nanoparticles can act as nucleation sites for this reaction, which results in the formation a mineralized surface on the nanoparticle core (Perkin et al., 2005) . CP formed away from the micelle particles can be removed easily, due to the insolubility of CP. DCA is a sterolbased bile acid that acts as an endogenous emulsifying agent by forming micelles to aid in interactions with insoluble compounds inside the body. The addition of sterol compounds to micelles has been previously shown to improve micelle stability and in vivo delivery (Oe et al., 2014) , as well as reduce drug release rates (Vakil and Kwon, 2008) .
As discussed previously, rapid CFZ metabolism in the body may lead to an insufficient accumulation of active drug in distal tumor sites. To better understand the relationship between the interactions of CFZ with the polymer micelle particles and the overall metabolic stability profile, we characterized the likely derived from stronger and more specific interactions between CFZ and the polymer micelle particles. Based on our results, both PM1 and PM2 were able to release CFZ in a sustained manner, suggesting that the difference in PCL content may not be the dominant factor in controlling CFZ release.
Furthermore, PM1-DCA and PM2-DCA appeared to release CFZ more slowly compared to polymer micelles that did not contain DCA, suggesting that interactions between DCA and CFZ may play a role in slowing CFZ release from micelle particles.
Our findings indicated that both the release rate and the metabolic profile of CFZ may be important in determining the overall efficacy of CFZ, but not with a straightforward relationship between rate of CFZ release and metabolic degradation. We found that PM1-CP and PM2-CP, which released CFZ quickly, had the least anti-cancer activities compared to other formulations. On the other hand, PM1-DCA and PM2-DCA, which had slower CFZ release, achieved better anti-cancer activity. These observations suggest that the rate of drug release plays a role in determining the overall efficacy of the drug, and that micelle particles with slower CFZ release may be better in inducing cancer cell death. In addition to having the quickest release profile, PM1-CP also demonstrated least in vitro metabolic stability among the six formulations. This may be an effect of the fast release of CFZ or instability in the structure of the particles that resulted in the breakdown of CFZ and thus poor efficacy in cells. PM2 particles were most effective in inducing cell death among all formulations, despite also possessing a fast CFZ release profile similar to that of PM1-CP. Interestingly, PM2 particles had good metabolic stability despite having quick CFZ release rates, suggesting that metabolic stability may depend on factors other than the rate of drug This article has not been copyedited and formatted. The final version may differ from this version. release. This is also consistent with the fact that differences observed in CFZ release in our study did not necessarily correspond to those observed in metabolic stability profiles. To better understand the necessary balance between drug stability and release rate, further optimizations in particle design and more in-depth assessments of metabolic stability and drug release in vivo will be necessary.
In our current study, we compared six polymer micelle formulations that displayed substantial protection of CFZ molecules from degradation in the presence of liver homogenates. The excipients CP or DCA added with an intent to stabilize the micelle core appeared to have an impact on drug release profiles. For example, PM1-DCA and PM2-DCA appeared to release the drug more slowly than polymer micelles without DCA added (Fig 2 and 
